SCHEDULE: FMR LLC Reports 9% Stake in Cytokinetics

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 9.0% of Cytokinetics Inc.'s common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating their beneficial ownership of Cytokinetics Inc. common stock.
• As of March 31, 2026, the aggregate amount beneficially owned is 11,135,192.23 shares.
• This represents 9.0% of the total outstanding common stock class.
• FMR LLC has sole voting power over 11,093,544.96 shares and sole dispositive power over 11,135,192.23 shares.
• Abigail P. Johnson is identified as a reporting person, with shared voting and dispositive power, and the same aggregate beneficial ownership as FMR LLC.
• The filing indicates that other persons may have the right to receive or direct the sale of these securities, but no single other person's interest exceeds five percent.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates significant and stable institutional ownership, but lacks operational or financial performance details.

Positives

• Significant institutional ownership reported by FMR LLC and Abigail P. Johnson, indicating confidence in Cytokinetics Inc.
• The reporting persons hold substantial voting and dispositive power over their stake.

Negatives

• The filing does not contain specific financial performance data or operational updates, focusing solely on ownership.

Risks

• The filing does not explicitly mention any risks.
• Potential for future changes in ownership stake by FMR LLC or Abigail P. Johnson could impact share price.

Future Outlook

This filing is a Schedule 13G, which reports beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant filings like this Schedule 13G from major institutional investors such as FMR LLC can signal sustained interest or a strategic shift in a biotechnology company like Cytokinetics, which operates in a highly competitive and capital-intensive sector.

Stakeholder Impact

• Shareholders may view the continued significant ownership by FMR LLC and Abigail P. Johnson as a positive indicator of institutional support.
• The filing does not provide information that would directly impact employees, customers, suppliers, or creditors.

Next Steps

• Continued monitoring of FMR LLC's and Abigail P. Johnson's ownership stake in Cytokinetics Inc.

Key Dates

Recommendation

This filing is purely informational regarding ownership and does not provide performance data or strategic updates that would warrant a buy or sell recommendation. A 'hold' is appropriate as it signifies continued institutional interest without new catalysts.

Keywords

Cytokinetics Inc, Schedule 13G, FMR LLC, Abigail P. Johnson, beneficial ownership, institutional investor, common stock, SEC filing